Low uptake of COVID-19 booster doses among elderly cancer patients in China: A multicentre cross-sectional study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: International Society of Global Health Country of Publication: Scotland NLM ID: 101578780 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-2986 (Electronic) Linking ISSN: 20472978 NLM ISO Abbreviation: J Glob Health Subsets: MEDLINE
    • Publication Information:
      Publication: <2019>-: Edinburgh : International Society of Global Health
      Original Publication: Edinburgh : Edinburgh University Global Health Society, 2011-
    • Subject Terms:
      COVID-19*/epidemiology ; Immunization, Secondary* ; Neoplasms*; Adult ; Aged ; Humans ; China/epidemiology ; COVID-19 Vaccines ; Cross-Sectional Studies ; SARS-CoV-2 ; Middle Aged
    • Abstract:
      Background: Vaccination is a crucial measure to control the spread of coronavirus disease 2019 (COVID-19) pandemic. The elderly and cancer populations both are more susceptible to SARS-CoV-2 and have higher mortality. However, the uptake of COVID-19 vaccine booster doses among elderly cancer patients remains unclear. This study aimed to investigate the prevalence and associates of COVID-19 vaccine booster doses uptake in elderly cancer patients.
      Methods: A multi-center cross-sectional survey was conducted in four general populations of China province from April to June 2022. Demographic and clinical characteristics, as well as COVID-19 vaccination status and reasons for not uptake booster doses, were collected through face-to-face interviews and medical records. Multivariable logistic regression models were performed to explore the associates of the first COVID-19 booster dose vaccination uptake of cancer patients.
      Results: A total of 893 cancer patients were eventually included in this study, of which 279 (31.24%) were aged 65 or older and 614 (68.76%) were under 65 years old. The proportion of the first COVID-19 vaccine booster dose among cancer patients aged 65 and above was lower than among adults aged 65 (23.66 vs. 31.92%). Factors affecting individual-level variables among the aged 65 and above cancer patients group whether to uptake the first COVID-19 booster dose were negative attitudes toward COVID-19 vaccine booster dose, perceived subjective norm, perceived behavioural control, and other types of chronic disease. There is no significant difference in the incidence of related adverse reactions between the two age groups (P = 0.19).
      Conclusions: Low uptake of COVID-19 vaccine booster doses among elderly cancer patients is a significant concern and implies high susceptibility and high fatality when facing the emergence of SARS Cov-2 outbreak. Efforts to improve vaccine education and accessibility, particularly in rural areas, may help increase uptake and reduce the spread of SARS-Cov-2.
      Competing Interests: Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.
      (Copyright © 2024 by the Journal of Global Health. All rights reserved.)
    • References:
      Support Care Cancer. 2022 Jan;30(1):289-293. (PMID: 34279721)
      Front Oncol. 2022 Oct 20;12:1002168. (PMID: 36338743)
      Cancer Discov. 2021 Oct;11(10):2430-2435. (PMID: 34475136)
      Vaccines (Basel). 2022 Aug 06;10(8):. (PMID: 36016158)
      AIDS Behav. 2022 Jul;26(7):2242-2255. (PMID: 35020094)
      Vaccine. 2015 Aug 14;33(34):4161-4. (PMID: 25896383)
      Signal Transduct Target Ther. 2022 May 3;7(1):146. (PMID: 35504917)
      PLoS One. 2021 Oct 28;16(10):e0259059. (PMID: 34710168)
      J Clin Oncol. 2022 May 1;40(13):1414-1427. (PMID: 35286152)
      Cancer Cell. 2021 Aug 9;39(8):1045-1047. (PMID: 34242573)
      Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541)
      Nat Med. 2022 Apr;28(4):831-837. (PMID: 35045566)
      Soc Sci Med. 2022 Mar;296:114767. (PMID: 35144226)
      Cancer Biol Med. 2021 Feb 15;18(1):298-307. (PMID: 33628602)
      Front Public Health. 2022 Dec 15;10:986916. (PMID: 36589991)
      Soc Sci Med. 2020 Jun;255:112946. (PMID: 32311515)
      Trop Med Infect Dis. 2022 Oct 13;7(10):. (PMID: 36288039)
      Vaccine. 2022 Nov 2;40(46):6649-6657. (PMID: 36210253)
      Cancer Cell. 2022 Jan 10;40(1):3-5. (PMID: 34838186)
      Cancer Cell. 2022 Jan 10;40(1):103-108.e2. (PMID: 34990570)
      Aust Health Rev. 2023 Feb;47(1):110-118. (PMID: 36476744)
      Vaccines (Basel). 2022 Mar 03;10(3):. (PMID: 35335020)
      Vaccines (Basel). 2022 Jun 17;10(6):. (PMID: 35746574)
      JAMA Oncol. 2022 Feb 1;8(2):281-286. (PMID: 34854921)
      BMC Infect Dis. 2021 Aug 21;21(1):855. (PMID: 34418980)
      Lancet. 2020 Nov 14;396(10262):1595-1606. (PMID: 33065034)
      Ann Oncol. 2020 Aug;31(8):1088-1089. (PMID: 32330541)
      Nature. 2021 Sep;597(7876):404-409. (PMID: 34340242)
      JAMA Netw Open. 2022 May 2;5(5):e2210880. (PMID: 35532936)
      J Med Internet Res. 2021 Sep 6;23(9):e29329. (PMID: 34280115)
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Subject Terms:
      COVID-19 vaccine booster shot
    • Publication Date:
      Date Created: 20240202 Date Completed: 20240209 Latest Revision: 20240209
    • Publication Date:
      20240210
    • Accession Number:
      PMC10835334
    • Accession Number:
      10.7189/jogh.14.05010
    • Accession Number:
      38303680